Stock Events

Stock Events

Geron 

$1.28
144
+$0+0% Today

Statistics

Day High
1.32
Day Low
1.29
52W High
1.95
52W Low
1.07
Volume
8,201,226
Avg. Volume
-
Mkt Cap
817.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.08
-0.06
-0.03
-0.01
Expected EPS
-0.007917
Actual EPS
N/A

Financials

-226.73%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
153.99MRevenue
-349.14MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GERN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap183.12B
Amgen is a biotechnology company focused on developing novel therapies, including for hematologic malignancies, which competes with Geron's focus on blood cancers.
Johnson & Johnson
JNJ
Mkt Cap564.11B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for various cancers, directly competing with Geron's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Bristol Myers Squibb offers a wide range of cancer treatments, including those for hematologic cancers, making it a direct competitor to Geron.
Novartis
NVS
Mkt Cap290.05B
Novartis is a global healthcare company with a significant presence in oncology, including research in treatments for blood cancers, competing with Geron's development focus.
Pfizer
PFE
Mkt Cap147.62B
Pfizer has a diverse oncology portfolio, including therapies for breast and hematologic cancers, positioning it as a competitor to Geron.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie, with its acquisition of Pharmacyclics, has expanded its oncology portfolio, including treatments for hematologic malignancies, competing with Geron's therapeutic area.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in cell therapies for cancer, including hematologic malignancies, competing with Geron's focus.
Merck
MRK
Mkt Cap302.33B
Merck & Co. is involved in the development of cancer treatments, including immunotherapies that could be used in treating hematologic cancers, making it a competitor to Geron.
Rogers
ROG
Mkt Cap2.41B
Roche, with its strong focus on oncology and a broad portfolio of cancer treatments, including for blood cancers, competes with Geron in the oncology space.

About

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Show more...
CEO
Mr. Harout Semerjian
Employees
229
Country
United States
ISIN
US3741631036

Listings

MI
IT
1GERN.MI
MU
DE
GON.MU
STU
DE
GON.STU
LSE
GB
0IV3.LSE

0 Comments

Share your thoughts

FAQ

What is Geron stock price today?▼
The current price of GERN is $1.28 USD — it has increased by +0% in the past 24 hours. Watch Geron stock price performance more closely on the chart.
What is Geron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Geron stocks are traded under the ticker GERN.
Is Geron stock price growing?▼
GERN stock has risen by +4.92% compared to the previous week, the month change is a -14.67% fall, over the last year Geron has showed a -11.72% decrease.
What is Geron market cap?▼
Today Geron has the market capitalization of 817.09M
When is the next Geron earnings date?▼
Geron is going to release the next earnings report on August 06, 2026.
What were Geron earnings last quarter?▼
GERN earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.02 USD resulting in a +50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Geron revenue for the last year?▼
Geron revenue for the last year amounts to 153.99M USD.
What is Geron net income for the last year?▼
GERN net income for the last year is -349.14M USD.
How many employees does Geron have?▼
As of May 26, 2026, the company has 229 employees.
In which sector is Geron located?▼
Geron operates in the Health & Wellness sector.
When did Geron complete a stock split?▼
Geron has not had any recent stock splits.
Where is Geron headquartered?▼
Geron is headquartered in Foster City, United States.